MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
2.200
+0.060
+2.80%
After Hours: 2.190 -0.01 -0.45% 19:26 05/14 EDT
OPEN
2.240
PREV CLOSE
2.140
HIGH
2.240
LOW
2.170
VOLUME
264.57K
TURNOVER
--
52 WEEK HIGH
28.61
52 WEEK LOW
1.790
MARKET CAP
11.74M
P/E (TTM)
-0.0774
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Q1 FY26 net loss widens to $12.85 million; operating loss widens to $7.87 million
PUBT · 8h ago
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target
TipRanks · 9h ago
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Benzinga · 1d ago
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
TipRanks · 1d ago
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
TipRanks · 1d ago
Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine
Benzinga · 1d ago
MOLECULIN BIOTECH INC - MIRACLE TRIAL ON TRACK TO COMPLETE PART A RECRUITMENT IN Q3 2026 - SEC FILING
Reuters · 1d ago
Moleculin nears MIRACLE trial unblinding for Annamycin in relapsed AML by June 30
PUBT · 1d ago
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.